Combination antibody therapy shows promise in metastatic melanoma
Friday, June 3, 2011 - 18:30
in Health & Medicine
A duo of monoclonal antibodies -- ipilimumab and bevacizumab -- each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial.
